Aqualung Therapeutics
Tucson, US · Founded 2021 · Delaware corporation · 1 known investors
Aqualung Therapeutics is an early-stage therapeutics company developing a drug discovery platform and pipeline focused on advancing human health. It is affiliated with the University of Florida biotech ecosystem.
Founders & leadership
Aqualung Therapeutics was founded in 2021 by Joe G.N. Garcia and Joe G.N. "Skip" Garcia.
Investors · 1
Reported raises · per SEC filings
Form D private placements$3.1M disclosed across 1 round · 2021
▶$3.1MraisedJun 2022 · 17 investors · BiotechnologyRule 506(b)
- Stan MieleExecutive Officer, Director
- Joe G.N. GarciaExecutive Officer, Director
- Offering amount
- $6M
- Amount sold
- $3.1M
- Minimum investment
- $10K
- First sale
- Sep 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapCompanies competing with Aqualung Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 13 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2023 | $975.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2023 | $809K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2022 | $269.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2022 | $259.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2022 | $259.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2021 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2020 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2020 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2020 | $265.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2019 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2019 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2011 | $631.2K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Aqualung Therapeutics do?
- Aqualung Therapeutics is an early-stage therapeutics company developing a drug discovery platform and pipeline focused on advancing human health. It is affiliated with the University of Florida biotech ecosystem.
- Who founded Aqualung Therapeutics?
- Aqualung Therapeutics was founded by Joe G.N. Garcia, Joe G.N. "Skip" Garcia in 2021.
- Who are Aqualung Therapeutics's investors?
- Aqualung Therapeutics's investors include 7G BioVentures.
- How much funding has Aqualung Therapeutics raised?
- Aqualung Therapeutics has disclosed $3.1M raised across 1 round.
- Where is Aqualung Therapeutics headquartered?
- Aqualung Therapeutics is headquartered in Tucson, US.

